【摘要】：正配體制藥公司宣布LGD-6972治療2型糖尿病的Ⅰb期臨床試驗(yàn)有較好的安全性、耐受性和藥代動(dòng)力學(xué)結(jié)果,證實(shí)其可劑量依賴性地降低空腹血糖。LGD-6972是胰高血糖素受體拮抗劑,能降低肝生成葡萄糖。試驗(yàn)表明,LGD-6972 5、10和15 mg是安全的且耐受良好。在血液、尿液、心電圖和生命體征方面檢測(cè)均未發(fā)現(xiàn)有臨床意義的變化,無(wú)嚴(yán)重不良反應(yīng)和停藥者。副作用均為1~2級(jí)輕中度。隨LGD-6972劑量增加,血藥濃度呈線性升高,正常人與2型糖尿病患者的藥代動(dòng)力學(xué)參數(shù)相當(dāng),支持每日1次用藥。LGD-6972能降低正
[Abstract]:The positive Ligand Pharmaceutical Company announced that the phase I b clinical trial of LGD-6972 in the treatment of type 2 diabetes mellitus has better safety, tolerance and pharmacokinetics results. It was confirmed that LGd-6972 was a glucagon receptor antagonist and decreased glucose production in the liver in a dose-dependent manner. The results showed that LGD-6972 5, 10 mg and 15 mg were safe and well tolerated. No clinical changes were found in blood, urine, electrocardiogram and vital signs, and there were no serious adverse reactions and withdrawal. The side effects were 1 鈮，

本文編號(hào)：2472934